We are live on
!
Find out more
EOJOAM
E. Ohman J:or Asset Management Portfolio holdings
AUM
$4.3B
1-Year Est. Return
29.55%
This Fund
S&P 500
This Quarter
Est. Return
+6.12%
1 Year Est. Return
+29.55%
3 Year Est. Return
+110.24%
5 Year Est. Return
+144.75%
10 Year Est. Return
+695.34%
AUM
$1.13B
AUM Growth
+$133M
(+13%)
Cap. Flow
+$76.8M
Cap. Flow
% of AUM
6.83%
Top 10 Holdings %
Top 10 Hldgs %
29.98%
Holding
565
New
6
Increased
343
Reduced
14
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$11.6M |
| 2 |
ICICI Bank
IBN
|
+$6.87M |
| 3 |
Verizon
VZ
|
+$6.14M |
| 4 |
Palo Alto Networks
PANW
|
+$6.09M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$4.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$5.32M |
| 2 |
AABA
Altaba Inc
AABA
|
+$4.73M |
| 3 |
MacroGenics
MGNX
|
+$3.45M |
| 4 |
Bank of America
BAC
|
+$2.88M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$2.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.83% |
| 2 | Financials | 18.55% |
| 3 | Consumer Discretionary | 14.98% |
| 4 | Communication Services | 14.5% |
| 5 | Healthcare | 14.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Microsoft
MSFT
$3.76T
| $51.8M | 4.6% |
695,418
+54,464
| +8% | +$3.98M |
|
2
Alphabet (Google) Class A
GOOGL
$4.37T
| $50M | 4.45% |
1,027,220
+73,660
| +8% | +$3.49M |
|
3
Apple
AAPL
$4.5T
| $45.2M | 4.02% |
1,173,804
+71,116
| +6% | +$2.76M |
|
4
Amazon
AMZN
$3T
| $42.3M | 3.76% |
879,000
+84,860
| +11% | +$4.17M |
|
5
Alibaba
BABA
$317B
| $34.3M | 3.05% |
198,400
-9,700
| -5% | -$1.57M |
|
6
Citigroup
C
$227B
| $31.2M | 2.77% |
428,836
-30,288
| -7% | -$2.07M |
|
7
Merck
MRK
$323B
| $24.1M | 2.14% |
394,150
+52,977
| +16% | +$3.21M |
|
|
8
Verizon
VZ
$195B
| $20.7M | 1.84% |
419,275
+130,508
| +45% | +$6.14M |
|
9
Cisco
CSCO
$483B
| $19.4M | 1.72% |
575,902
+71,756
| +14% | +$2.28M |
|
|
CELG
10
DELISTED
Celgene Corp
CELG
| $18.3M | 1.63% |
125,566
+26,496
| +27% | +$3.61M |
|
11
PayPal
PYPL
$50.5B
| $18.1M | 1.61% |
283,285
-21,833
| -7% | -$1.31M |
|
|
12
Bank of America
BAC
$447B
| $17.8M | 1.58% |
700,638
-118,739
| -14% | -$2.88M |
|
13
Visa
V
$675B
| $17.3M | 1.54% |
164,172
+31,842
| +24% | +$3.23M |
|
14
Starbucks
SBUX
$119B
| $17.2M | 1.53% |
319,468
+60,688
| +23% | +$3.36M |
|
15
Thermo Fisher Scientific
TMO
$222B
| $16.6M | 1.48% |
87,946
-4,914
| -5% | -$890K |
|
16
Goldman Sachs
GS
$301B
| $16.2M | 1.44% |
68,468
+20,396
| +42% | +$4.6M |
|
17
Meta Platforms (Facebook)
META
$1.52T
| $15.5M | 1.38% |
90,919
+2,100
| +2% | +$350K |
|
18
Trip.com Group
TCOM
$29.7B
| $15.5M | 1.38% |
294,450
+58,753
| +25% | +$3.19M |
|
|
19
Alphabet (Google) Class C
GOOG
$4.35T
| $15.5M | 1.37% |
322,440
+3,680
| +1% | +$171K |
|
20
Walt Disney
DIS
$178B
| $15.4M | 1.37% |
156,144
+30,742
| +25% | +$3.16M |
|
|
21
ICICI Bank
IBN
$108B
| $15.2M | 1.35% |
1,773,931
+752,138
| +74% | +$6.87M |
|
|
22
Eli Lilly
LLY
$1.1T
| $14.4M | 1.28% |
168,132
+141,932
| +542% | +$11.6M |
|
23
Biogen
BIIB
$30.6B
| $14.3M | 1.27% |
45,786
+96
| +0.2% | +$28.4K |
|
24
Prologis
PLD
$132B
| $14.1M | 1.25% |
221,508
+37,138
| +20% | +$2.29M |
|
25
Adobe
ADBE
$109B
| $14M | 1.24% |
93,600
+1,200
| +1% | +$179K |
|
Similar funds
IWM
CW
IUHSA
MYIA
NEI
CIC
SLI
E. Ohman J:or Asset Management's Q3 2017 Portfolio in Review
As of Q3 2017, E. Ohman J:or Asset Management held 565 positions worth $1.13B, up 13% from $992M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
E. Ohman J:or Asset Management deployed $76.8M of net new capital in Q3 2017, opening 6 new positions and adding to 343 existing holdings. Its largest new stake was Teva Pharmaceuticals: 206,483 shares worth $3.63M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Hologic, an estimated $5.32M trimmed.
- E. Ohman J:or Asset Management's largest Q3 2017 buy was Teva Pharmaceuticals: 206,483 shares worth $3.63M.
- E. Ohman J:or Asset Management added most to Eli Lilly in Q3 2017, an estimated $11.6M increase.
- E. Ohman J:or Asset Management's biggest Q3 2017 reduction was Hologic, cutting an estimated $5.32M.
- E. Ohman J:or Asset Management fully exited MacroGenics in Q3 2017, selling an estimated $3.45M.
- E. Ohman J:or Asset Management's ten largest holdings make up 30% of its $1.13B portfolio in Q3 2017.
- E. Ohman J:or Asset Management opened 6 new positions and closed 6 in Q3 2017.
- E. Ohman J:or Asset Management's portfolio value rose 13% quarter-over-quarter to $1.13B.
Based on E. Ohman J:or Asset Management's 13F filing for Q3 2017, filed 5 Apr 2024.